移植肾受者的骨质疏松研究进展  

Research progress of osteoporosis in renal transplant recipients

作　　者：付雪梅[1] 王亮[2] 马远征[2] 李州利[2] 张妍[2] 苏天娇[2] 陈立英[2] 徐小文[2] 马伟凤[2] 谢媛媛[2] 杨帆[2] 马彦巧 陈琼[2] 王天天[2] 孙杨[2] 

机构地区：[1]山西医科大学,太原030001 [2]解放军第309医院骨科中心,北京100091

出　　处：《中国骨质疏松杂志》2015年第12期1508-1511,共4页Chinese Journal of Osteoporosis

摘　　要：骨质疏松症是肾移植患者常见的并发症之一,严重影响到移植肾受者的生活质量,造成移植肾受者骨量减低的原因是多方面的,其中重要的原因之一就是激素的长期应用。由于肾移植患者须合用糖皮质激素及其他免疫抑制剂以控制症状,但其最佳剂量既可最大地控制患者病情,又可尽可能小地减少对肾移植受者骨量产生影响仍有待进一步地研究与统一。为了尽可能地改善移植肾受者的骨量以提高其生存质量,有多项研究资料表明,维生素D与膦酸盐类药物可能会改善肾移植受者的骨密度。Osteoporosis is a common complication in renal transplantation patients. It seriously affects thequality of lifein renal allograft recipients. Thecauseof bonemass loss in graft recipients is various. Oneof theimportant reasons is thelong-term application of hormones. Renal transplant patients haveto betreated with corticosteroids and other immunosuppressiveagents to control thesymptoms. However,theoptimal dosethat not only can control thepatient＇s condition,but also can reduceits influenceto bonemass in renal transplant recipients,remains to bestudied and integrated. A number of research data showthat both vitamin D and bisphosphonates may improvethebonemineral density in therenal transplant recipients,resulting in improved bonemass and thequality of lifein therenal allograft recipients,

关 键 词：骨质疏松 移植肾受者 骨密度 糖皮质激素 维生素D 膦酸盐类药物 

分 类 号：R589.5[医药卫生—内分泌]